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Background: The Graffi murine retrovirus is a powerful tool to find leukemia associated oncogenes. Using DNA
microarrays, we recently identified several genes specifically deregulated in T- and B-leukemias induced by this
virus.
Results: In the present study, probsets associated with T-CD8+ leukemias were analyzed and we validated the
expression profile of the Parm-1 gene. PARM-1 is a member of the mucin family. We showed that human PARM-1 is
an intact secreted protein accumulating predominantly, such as murine PARM-1, at the Golgi and in the early and
late endosomes. PARM-1 colocalization with α-tubulin suggests that its trafficking within the cell involves the
microtubule cytoskeleton. Also, the protein co-localizes with caveolin-1 which probably mediates its internalization.
Transient transfection of both mouse and human Parm-1 cDNAs conferred anchorage- and serum-independent
growth and enhanced cell proliferation. Moreover, deletion mutants of human PARM-1 without either extracellular
or cytoplasmic portions seem to retain the ability to induce anchorage-independent growth of NIH/3T3 cells. In
addition, PARM-1 increases ERK1/2, but more importantly AKT and STAT3 phosphorylation.
Conclusions: Our results strongly suggest the oncogenic potential of PARM-1.
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The Graffi murine leukemia virus (MuLV) induces a
wide spectrum of leukemias in several strains of mice,
including lymphoid and non-lymphoid types [1,2] mak-
ing of this virus a good model to gain new insights on
lymphoid leukemia development and progression and to
identify new oncogenes. Retroviruses have been used as
molecular tools to identify oncogenes or tumor suppres-
sors directly targeted through the retroviral integration.
However the microarray technology is attractive because
it allows identifying, in addition to the retrovirus
targeted genes, those involved in the cascade of events
that leads to cell transformation, tumor progression,
cancer and metastasis. We therefore used this approach
to compare the transcriptome of a full panel of leuke-
mias induced by the Graffi MuLV [2] and we focused
our analyses on the lymphoid types [3]. We identified
genes that were deregulated in one type of leukemia* Correspondence: edouard.elsy@uqam.ca; rassart.eric@uqam.ca
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reproduction in any medium, provided the orwhen compared to the corresponding control, therefore
representing potential markers and oncogenes or tumor
suppressor candidates that are specific for B, T or com-
mon to both types of leukemia. As expected, many of
these genes were known to be specific to a lineage and
to leukemia types (for details, see: [4]). Furthermore, we
validated changes in the expression levels of 10 genes
selected according to their specificity for lymphoid
leukemias. These results clearly validated our approach
and identified genes that now deserve more attention.
Indeed, we previously reported that the Fmn2 gene har-
bors oncogenic potential. It was found specifically over-
expressed in murine B-leukemias as well as in human
pre-B-ALL especially in children bearing a t(12;21)
translocation (TEL/AML1 rearrangement) [3].
In this study, we focused on genes that are associated
with T-CD8+ leukemias. We identified Parm-1 (prostate
androgen-regulated mucin-like protein 1), a gene specif-
ically up-regulated in T-CD8+ leukemias induced by
Graffi virus. PARM-1 is a member of the mucin family.
Very little is known about the physiological andtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cellular transformation has not been fully explored.
We characterized the function of PARM-1 and we inves-
tigated the oncogenic potential of mouse and human pro-
teins. PARM-1 is a weakly secreted protein which contains
a transmembrane domain (TM) and a cytoplasmic tail
(CT) in addition to the extracellular (EC) domains. Both
human (hPARM-1) and mouse (mPARM-1) proteins are
predominantly located at the Golgi and in the early and late
endosomes but transiently located at the plasma mem-
brane. PARM-1 trafficking within the cells seems associated
with the microtubule cytoskeleton. Also, PARM-1 induced
both anchorage and serum-independent growth, enhanced
cell proliferation and activated ERK1/2, AKTand STAT3.
Together, these results provide strong evidences for
the oncogenic potential of PARM-1 and emphasize their
important role in leukemogenesis.
Results
Microarray data analyses and validation of mParm-1
association with T-CD8+ leukemias
In our previous study, to gain insight into the cancerous
signatures of lymphoid leukemias, the gene expression
profile of three T-leukemias and of three B-leukemias
induced by the Graffi MuLV was analyzed using
microarrays technology and compared to those of non-
leukemic B- and T-cells, respectively [3]. We identified a
set of genes that are specific markers for Graffi MuLV-
induced B and T leukemias. In this study, we focused on
genes that were only associated with T-CD8+ leukemias.
Accordingly, 42 probsets (32 genes) were over-expressed
and 8 probsets (7 genes) were down-regulated. Some
were already associated with T-CD8+ leukemias (Il2ra
[5]; and Pdgfrb [6]) and others were associated with
other types of T-leukemias or cancer (Irf4 [7], Hrb [8],
Depdc6 [9], Als2cl [10], Tle4 [11] and Cdc42ep3 [12])
(Table 1), thus validating our approach. Interestingly,
many other genes were neither associated with leuke-
mias nor with other types of cancer, or had no assigned
function representing therefore good candidates as spe-
cific markers, oncogenes or tumor suppressors for
T-CD8+ leukemias. The complete list of these probsets
is presented in Table 1.
We focused on the mParm-1 (9130213B05Rik) gene. The
expression level of mParm-1 was measured by semi-
quantitative RT-PCR in several Graffi MuLV-induced
tumors. Significant over-expression was only observed in
T-CD8+ tumors when compared to control T-cells. This
result confirms the specificity of the mParm-1 gene up-
regulation to T-CD8+ leukemias (Figure 1).
PARM-1 sequence analysis
PARM-1 is a member of the mucin family known to be
expressed at the surface of many epithelial cells [13] topromote cell survival by protecting the cell surface and
to be implicated in cancer development [14]. Protein se-
quence analysis of mPARM-1 showed that, as the
hPARM-1 and in addition to its single transmembrane
domain, mPARM-1 possess an N-terminal signal peptide
(Figure 2a and 2b) [15]. mPARM-1 sequence contains 3
N-glycosylated motifs and 65 mucin-type O-glycosylated
sites [16], suggesting that, as its human counterpart,
mPARM-1 should be highly glycosylated. Moreover, we
found that 41% of the amino acid composition of
mPARM-1 is represented by serine, proline and threo-
nine residues similar to the human protein [17]. Interest-
ingly, amino acid sequence alignment of PARM-1
homologs showed that the C-terminus is highly conserved
(Additional file 1: Figure S1) suggesting an important role
through evolution.
PARM-1 protein characterization
The EC domain of most transmembrane mucins is re-
leased from the cell surface and we verified if this was
the case for PARM-1. Culture supernatant of NIH/3T3
cells transfected with hParm-1-GFP was collected and
the presence of hPARM-1 visualized by western blot
using either anti-hPARM-1 (specific for the EC portion)
or anti-GFP antibodies (specific for the GFP tag in
C-terminal). Lysates from NIH/3T3 expressing hPARM-
1-GFP were also analyzed. Using the anti-hPARM-1
antibody, hPARM-1-GFP was detected in the super-
natant as a very faint band slightly lower than 100-kDa.
We then used two deletion mutant constructs, one de-
leted for the TM and CT domains (EC-GFP, Figure 2c)
and the other missing only the CT portion (ΔCT-GFP,
Figure 2d) of hPARM-1. Our results showed that ΔCT-
GFP mutant protein was also secreted in approximately
the same proportion and size as the full-length con-
struct. However, the EC-GFP mutant was found to be
secreted as two bands: one intense band of about 90-
kDa and a weaker band of about 70-kDa (Figure 3a; See
Additional file 2: Figure S2 to compare the molecular
weight of all the obtained bands). The abundance of EC-
GFP in both the cell lysate and the supernatant probably
reflects protein stability (Figure 3a and Additional file 2:
Figure S2). Surprisingly, anti-GFP antibodies detected
the secreted protein for the three constructs at the same
molecular weight as for the anti-hPARM-1 antibodies
(Figure 3b and Additional file 2: Figure S2) suggesting
that the protein could be entirely secreted since the GFP
tag is located at the C-terminal end. We could not de-
tect actin in these supernatants excluding contamination
from lysed cells. These results suggest that PARM-1 is a
secreted intact protein.
Using the anti-GFP antibody, we noted a more com-
plex expression pattern of hPARM-1-GFP in the lysates
from NIH/3T3 transfected cells than that obtained with
Table 1 Probsets associated with T CD8+leukemias
ProbesetIDs T1-CT T2-CT T3-CT B1-CT B2-CT B3-CT Gene Title Gene Symbol
* * * * * *
T CD8+ overexpressed genes
1420692_at 5,83 5,52 −0,02 −0,21 0,12 0,52 interleukin 2 receptor, alpha chain Il2ra
1456645_at 5,75 5,21 0,85 −0,23 −0,14 −0,14 WD repeat domain 25 Wdr25
1435436_at 5,70 5,77 0,77 −0,02 −0,05 0,28 Transcribed locus —
1427802_a_at 5,63 7,13 −0,14 0,53 −0,22 −0,33 — —
1436970_a_at 5,35 7,13 0,87 0,22 −0,73 0,01 platelet derived growth factor receptor, beta polypeptide Pdgfrb
1428420_a_at 4,88 4,98 −0,12 −0,19 −0,42 −0,19 RIKEN cDNA 1200009I06 gene Exoc3l4
1419302_at 4,39 4,77 0,10 0,65 0,51 0,17 hairy/enhancer-of-split related with YRPW motif-like Heyl
1440808_x_at 4,20 3,61 0,02 −0,62 −0,45 −0,58 CD163 molecule-like 1 Cd163l1
1420691_at 4,19 4,39 −0,17 −0,10 0,12 0,45 interleukin 2 receptor, alpha chain Il2ra




1459461_at 4,04 5,39 0,24 0,54 0,67 0,44 — —




1460294_at 3,84 4,65 0,16 −0,20 −0,20 0,15 ATPase, aminophospholipid transporter-like, class I, type 8A,
member 2
Atp8a2
1440156_s_at 3,84 3,80 0,51 −0,13 −0,28 −0,35 TOX high mobility group box family member 2 Tox2
1435494_s_at 3,76 7,29 0,37 0,07 −0,12 0,00 desmoplakin Dsp
1455527_at 3,59 3,34 0,29 −0,25 −0,30 −0,16 CD163 molecule-like 1 Cd163l1
1444696_at 3,34 3,50 −0,04 0,22 −0,15 0,18 Transcribed locus, weakly similar to NP_001311.3 casein kinase 2,
beta polypeptide [Homo sapiens]
1421173_at 3,33 2,23 0,17 −0,63 −0,10 −0,60 interferon regulatory factor 4 Irf4
1440627_at 3,31 5,10 0,10 −0,19 −0,49 −0,47 ATPase, aminophospholipid transporter-like, class I, type 8A,
member 2
Atp8a2
1446224_at 3,22 3,00 0,97 −0,13 −0,26 −0,26 HECT domain containing 2 Hectd2
1438886_at 3,12 3,09 0,29 −0,03 −0,22 0,13 hairy/enhancer-of-split related with YRPW motif-like Heyl
1459219_at 3,09 5,30 −0,36 0,32 0,51 0,14 RIKEN cDNA B930012P20 gene Rapgef2
1426922_s_at 3,06 3,55 0,45 0,25 0,63 0,12 HIV-1 Rev binding protein Hrb
1433906_at 3,01 5,03 0,00 −0,01 −0,05 0,10 Clavesin 1 Clvs1
1450897_at 2,81 3,83 −0,62 −0,44 −0,62 −0,46 expressed sequence AU014947 AU014947
1451348_at 2,74 4,18, −0,55 0,77 0,58 0,38 DEP domain containing 6 Depdc6
1452237_at 2,71 3,29 0,38 −0,11 0,15 −0,02 HIV-1 Rev binding protein Hrb
1440870_at 2,56 3,69 −0,33 0,01 0,00 0,10 PR domain containing 16 Prdm16
1426923_at 2,46 2,90 0,14 −0,07 0,23 −0,01 HIV-1 Rev binding protein Hrb
1421508_at 2,45 2,02 −0,78 −0,44 −0,63 −0,28 odd Oz/ten-m homolog 1 (Drosophila) Odz1
1424814_a_at 2,45 2,31 0,59 −0,41 −0,60 −0,95 Bcl2-like 14 (apoptosis facilitator) Bcl2l14
1452238_at 2,44 3,31 0,09 0,24 0,28 −0,04 HIV-1 Rev binding protein Hrb
1423194_at 2,43 2,44 −0,27 −0,89 −0,57 −0,68 — —
1441548_at 2,39 2,76 −0,23 0,04 −0,21 −0,25 FERM domain containing 4B Frmd4b
1456956_at 2,36 3,95 0,56 −0,31 −0,59 −0,94 IKAROS family zinc finger 2 Ikzf
1434186_at 2,29 2,86 −0,40 0,00 −0,08 0,18 G protein-coupled receptor 23 Gpr23
1428622_at 2,23 3,86 0,08 0,66 0,66 0,75 DEP domain containing 6 Depdc6
1455449_at 2,19 4,11 −0,22 0,17 0,33 0,18 RIKEN cDNA 2010107G12 gene Gm468
1423666_s_at 2,13 2,18 0,90 0,82 0,88 0,35 ribosomal protein L5 Rpl5
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Table 1 Probsets associated with T CD8+leukemias (Continued)
1430029_a_at 2,04 2,22 −0,44 0,31 0,24 0,24 sarcoma amplified sequence Sas
1437542_at 2,02 2,39 0,87 0,38 0,21 −0,15 IKAROS family zinc finger 2 Ikzf2
1427132_at 2,00 2,18 0,42 −0,62 −0,36 −0,81 myotubularin related protein 13 Mtmr13
T CD8+ underexpressed genes
1433769_at −2,00 −4,28 0,03 −0,21 −0,26 −0,31 ALS2 C-terminal like Als2c
1424338_at −2,20 −2,20 0,62 −0,16 −0,98 0,20 solute carrier family 6 (neurotransmitter transporter, GABA),
member 13
Slc6a13
1420918_at −3,43 −2,50 −0,26 −0,72 0,07 −0,01 serum/glucocorticoid regulated kinase 3 Sgk3
1450455_s_at −3,49 −3,04 −0,73 −0,29 −0,22 0,09 aldo-keto reductase family 1, member C12 /// aldo-keto reductase
family 1, member C13
Akr1c12 ///
Akr1c13
1420919_at −3,54 −2,36 −0,18 −0,01 0,44 0,49 serum/glucocorticoid regulated kinase 3 Sgk3
1450853_at −3,59 −2,77 0,36 0,28 0,04 0,74 transducin-like enhancer of split 4, homolog of Drosophila E(spl) Tle4
1452657_at 4,09 2,04 0,29 0,17 −0,67 −0,87 adaptor-related protein complex 1, sigma 2 subunit Ap1s2
1450700_at −4,12 −2,08 −0,86 0,64 0,28 0,70 CDC42 effector protein (Rho GTPase binding) 3 Cdc42ep3
Results are presented in log base 2. A positive deviation of 4 and above and a negative deviation of 4 and below means a fold-change of 4. Values comprised
between 0,585 and −0,585.
*ratio T-CT and B-CB: mean of the deviation of T1, T2 and T3/T control value and mean of the deviation of B1, B2 and B3/B control value.
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-GFP construct, in addition to the 2 bands of about 80-
kDa and 120-kDa (probably a highly glycosylated and
homodimeric forms, respectively) detected by the anti-
hPARM-1 antibody, two other intense bands with a
lower size (between 30 and 40-kDa) were detected by
the anti-GFP antibody. These bands may result from
a cleavage liberating the C terminus of hPARM-1
(Figure 3a and 3b and Additional file 2: Figure S2). Simi-
lar result was obtained for the cell lysates of NIH/3T3
transfected with mParm-1-GFP. Using anti-GFP anti-
bodies, five bands were obtained: one over 100-kDa, one































Figure 1 Analysis of mParm-1 gene expression in sorted lymphoid leu
and 5 T leukemias : (B4, Cd45+Cd19+Sca1+; B5, Cd45R+Cd19+Sca1+; B6, Cd4
Cd4+Cd8+; T5, Cd4+Cd8+; T6, Cd4+Cd8+; T7, Cd4+Cd8+; T8, Cd4+Cd8-). RT-P
primer: 5’- tgacggggtcacccacactgtgcccatcta-3’, reverse primer: 5’-ctagaagca
gttagctgttttggggacca-3’, reverse primer: 5’-cgtgcaaattagcatctgga-3’) specific
density was quantified with Quantity One Image Software. The actin gene
are presented as a gene/actin density ratio. Data are representative of 3 ind
way analysis of variance, and P lower to 0.05 was considered to be signific
control (CB2, B cells from normal spleen and CT2, T cells from normal thym(Figure 3c and Additional file 2: Figure S2). Unfortu-
nately, the anti-hPARM-1 was not able to recognize the
murine protein.
PARM-1 colocalizes with the Golgi apparatus and with
early and late endosomes
We were interested to confirm that hPARM-1 protein is
localized to the Golgi, at the early endocytic pathway
and at the plasma membrane [17] and investigated the
localization of the murine protein in NIH/3T3 cells.
Both mPARM-1-GFP or hPARM-1-GFP proteins were
localized at the Golgi and have punctate and typical



















kemia samples. Semi-quantitative RT-PCR analysis of Parm-1 in 5 B
5R+Cd19+Sca1+; B7, Cd45R+Cd19+Sca1+; B8, Cd45R+Cd19+Sca1+) (T4,
CRs were performed in triplicate using the following actin (forward
tttgcggtggacgatggaggg-3’) and murine Parm-1 (forward primer: 5’-
primers. PCR products were analyzed on agarose gel and band
was used as internal control and expression levels in each leukemia
ependent experiments. Statistical analysis was performed using one-


















Figure 2 Schematic representation of full-length and deletion mutant constructs of mPARM-1 and hPARM-1. (a and b) Full-length
constructs of the mouse (296 a.a) and human PARM-1 (310 a.a). (c to g) representation of the human deletion mutants. SP: signal peptide: (1–20
a.a), EC: extracellular domain (mPARM-1: 20–246 a.a; hPARM-1: 20–260 a.a), TM: transmembrane domain (mPARM-1: 246–266 a.a; hPARM-1:
260–280 a.a), and CT: cytoplasmic tail (mPARM-1: 266–296 a.a; hPARM-1: 280–310 a.a). EGFP was fused in the C-terminal end of all constructs.
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tion with much less plasmid (data not shown), indicating
that neither the GFP tag, nor the over-expression of
PARM-1 disturbed its localization. The Golgi colocalization
was confirmed following cell staining with the bodipy Golgi
marker (Figure 4b). To quantify this colocalization, the
Pearson’s correlation coefficient (Rr) was calculated using
the ImageJ software. The values are ranged from 1 (perfect
correlation) to −1 (perfect exclusion), zero corresponding
to random localization. The Rr values are 0.68 for hPARM-
1-GFP and 0.74 for mPARM-1-GFP confirming the
colocalization of both human and murine PARM-1 with
the golgi marker. The endosomal colocalization was also
confirmed following immunolabelling of cells with anti-
Rab5 (hPARM-1-GFP (Rr: 0.83); mPARM-1-GFP (Rr:
0.54)) and anti-Rab7 (hPARM-1-GFP (Rr: 0.86); mPARM-
1-GFP (Rr: 0.88)) antibodies (Figure 4c and 4d). Surpris-
ingly, localization at the plasma membrane was very weak
for both proteins in NIH/3T3 (Figure 4a-d) and Jurkat T-
cells (Rr: 0.2) transiently transfected with hParm-1-
GFP (Figure 4e) and following cell membrane markerstaining (Figure 4f ) demonstrating that mPARM-1 has
the same localization as its human homolog.
NIH/3T3 cells were transfected with different hParm-
1-GFP deletion mutants. ΔEC-GFP and ΔSP-GFP have
the same localization as the hPARM-1-GFP (Figure 4g
and 4h). EC-GFP and ΔTM-GFP showed a diffuse
localization through all cellular compartments (Figure 4i
and 4j). ΔCT-GFP showed the same localization as the
full-length hPARM-1-GFP. However, this mutant is
clearly localized at the plasma membrane as well as in
the intracellular compartment (Figure 4k). These results
suggest that the TM probably determines Golgi-endocytic
pathway localization and that the CT inhibits plasma
membrane localization of PARM-1.
PARM-1 recycling
To monitor trafficking of PARM-1, NIH/3T3 cells were
transfected with hPARM-1-GFP construct and subjected
to live cell time-lapse microscopy. Cells incubated at
37°C showed highly motile hPARM-1-GFP vesicles, trav-









































Figure 3 PARM-1 protein profile and secretion by NIH/3T3 cells. Immunoblotting of lysates (30 μg) from NIH/3T3 cells transiently transfected
with expression vector of hParm-1 (full-length or mutants) or of mParm-1 using (a) an anti-hPARM-1 (Sigma; 1:1000) antibody or (b) an anti-GFP
(Santa Cruz Biotechnology; 1:1000) antibody. Culture supernatants from these cells were collected, centrifuged, concentrated and subjected to
SDS-PAGE (12 %) and hPARM-1 protein was detected by western blot (a) using anti-hPARM-1 and (b) anti-GFP antibodies recognizing
respectively the N-terminus and C-terminus of hPARM-1 fusion protein. The region below 80-kDa from the supernatant in panels a and b
contains no detectable bands. The anti-β-actin (Sigma; 1:1000) was used to detect possible media contaminations by proteins from lysed cell.
(c) mPARM-1 expression was also tested in cell lysates.
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side the cell (Additional file 3: Movie S1 (left panel)). Some
particles shuttled over short distances between plasma
membrane and a close compartment that may represent
early endosomes suggesting a fast-recycling pathway. Some
other vesicles recycled from plasma membrane and traveled
over longer distances suggesting a slow-recycling pathway[18] (Additional file 3: Movie S1 (left panel)). Since low
temperature are known to inhibit all active processes in-
cluding endocytosis [19], transfected NIH/3T3 cells were
incubated at 4°C. We showed that the motility of hPARM-
1-GFP vesicles was inhibited when compared to that in
cells at 37°C indicating that recycling of hPARM is energy
































Figure 4 Subcellular localization of mPARM-1 and hPARM-1 (full-length and mutant proteins). (a) NIH/3T3 cells, transiently transfected
with GFP-tagged mParm-1 or hParm-1 constructs were visualized using confocal microscopy. (b) For the Golgi co-localization, transfected NIH/
3T3 cells were fixed and stained with Bodipy ceramide marker. For late and early endosomes co-localization, fixed cells were labeled with (c) anti-
Rab5 (early endosomes (1:100, Cell signaling)) and (d) anti-Rab7 (late endosomes (1:100, Cell signaling)) antibodies, respectively. Jurkat T cells,
transiently transfected with hParm-1-GFP proteins were visualized (e) without fixation or (f) following fixation and staining with CellMask plasma
membrane labeling. NIH/3T3 cells were transiently transfected with (g) ΔEC-GFP, (h) ΔSP-GFP, (i) EC-GFP, (j) ΔTM-GFP and (k) ΔCT-GFP constructs
of hPARM-1 and visualized using confocal microscopy. (l) hPARM-1-GFP co-localizes with microtubules. NIH/3T3 cells transfected with hParm-1
-GFP construct were fixed and stained with anti-α-tubulin (1/2000, Sigma) antibody. Arrows indicate co-localized hPARM-1-GFP vesicles and
microtubules. NIH/3T3 cells transiently expressing (m) hPARM-1-GFP or (n) ΔCT-GFP were fixed, immunostained for caveolin-1 (1:100, Novus
Biologicals), and examined by confocal fluorescence microscopy. For hPARM-1-GFP-caveolin-1 co-localization, cells that clearly demonstrated cell
membrane PARM-1 localization were chosen. All co-localizations were observed following merging images of GFP-tagged proteins with those of
Golgi, endosomes, plasma membrane, α-tubulin or caveolin-1 labeling. Cells were imaged with a laser-scanning confocal microscope (Bio-Rad
MRC-1024 ES) mounted on a Nikon TE-300 using a Plan Apochromat 60x (NA 1.40) oil objective (Nikon), digitally acquired using Laser Sharp
software Version 3.2 (Bio-Rad). For live cell imaging, signals were collected at a rate of 2 seconds. Images were analyzed using NIH ImageJ Version
1.42l software. Data are representative of 3 independent experiments.
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Observing the cells incubated at 37°C, we found that
hPARM-1-GFP travels in a linear fashion, most likely
along the microtubules. When transfected NIH/3T3 cells
were stained with the anti-α-tubulin antibody, we
showed that some vesicles clearly localized along the
microtubule cytoskeleton (Rr: 0.33) (Figure 4l). When
treated with nocodazole, cells expressing hPARM-1-GFP
showed a drastic inhibition of vesicular movement and
a more pronounced hPARM-1-GFP expression at
the cell surface (Additional file 4: Movie S2). These re-
sults emphasize the important role of tubulin network
in hPARM-1 trafficking and demonstrate that its
destabilization leads to PARM-1-GFP accumulation at
cell periphery.
PARM-1 colocalizes with caveolin-1
The subcellular localization of the hPARM-1-GFP and
caveolin-1 was determined in NIH/3T3 cells. We
found that hPARM-1 and caveolin-1 proteins co-
localized at the plasma membrane as well as in a few
intracellular vesicular pools (Rr: 0.72) (Figure 4m).
This result was also confirmed using the ΔCT-GFP
mutant which also co-localized with caveolin-1 (Rr:
0.74) (Figure 4n).
PARM-1 enhances proliferation and serum-
independent growth
Transfected NIH/3T3 cells were tested for cell-cycle pro-
gression by FACS analysis. We found that the percentage of
NIH/3T3 cells transfected with mParm-1 or hParm-1 in S
phase is enhanced by 2 fold compared to control cells
(Figure 5a). Also, BrdU incorporation in NIH/3T3
cells transfected with either mParm-1-pcDNA3.1A or
hParm-1-pcDNA3.1A was 50% higher than that of
controls (Figure 5b and 5c) suggesting that PARM-1 is
a positive cell-cycle regulator.
Over-expression of either mPARM-1 or hPARM-1-GFP
in NIH/3T3 cells grown in the presence of 2.5%, 5% or 10%
serum concentrations promoted cell-proliferation com-
pared to control (Figure 6a) indicating that PARM-1 pro-
teins mediate induction of serum-independent cell growth
of NIH/3T3.
PARM-1 protein induces anchorage-independent growth
Classical assay of anchorage-independent growth was
performed. We noted that colonies formed in soft
agar were much more abundant in both mPARM-1
and hPARM-1-expressing cells compared to controls
(Figure 6 be and 6c). Similar result was obtained when
GFP-tagged proteins were used (data not shown). These
results suggest that both PARM-1 conferred anchorage
independence to NIH/3T3 cells.To identify which portion of hPARM-1 protein could
be involved in its oncogenic effect, ΔCT-GFP, ΔEC-
GFP and hPARM-1-GFP constructs were used. As a
positive control, cells were transfected with the human
Ras oncogene (EJ 6.6). Surprisingly, both ΔCT-GFP
and ΔEC-GFP mutants increased the number of
colonies in soft agar when compared to control cells
(Figure 6d). This increase was however lower than
that obtained with hPARM-1-GFP in particular for
ΔEC-GFP (P < 0.057). These results suggest the im-
portance of the TM-domain and probably a coopera-
tive relationship between the EC- and CT-domains of
hPARM-1.
It is important to note that the transient transfection
efficiencies in Figures 5 and 6 are ~50%, and therefore
the effects observed are actually underestimates of the
ability of PARM-1 to change cell growth properties.
PARM-1 protein over-expression modulates ERK1/2, AKT,
and STAT3
We showed that both PARM-1 proteins promote NIH/
3T3 cells proliferation but the implication of a specific
pathway by this protein remains to be determined. Acti-
vations of ERK1/2 [20], AKT [21] and STAT3 [22]
dependent signaling pathway are often linked to cell pro-
liferation. The analysis of the phosphorylation levels of
ERK1/2, AKT and STAT3 in cell lysates from NIH/3T3 fi-
broblasts overexpressing mPARM-1 or hPARM-1 showed
an up-regulation of their phosphorylation state (especially
for AKT and STAT3) (Figure 7a-c) indicating that PARM-1
affect and activate the ERK1/2, AKT, and STAT3
dependent signaling pathways.
Discussion
The raw microarrays results obtained in our previous
microarrays analysis were reanalyzed focusing on genes that
were specifically deregulated in T-CD8+ leukemias when
compared to T-cells control. From this analysis 50 probsets
were selected (Fold-change of 4). Some of these genes were
already known to be involved in T-CD8+ leukemias: Il2ra
(expressed in primary leukemia cells from a patient with
T-CD8+ prolymphocytic leukemia) [5]. Our microarray
analysis also showed that some other genes were known to
be associated with other T-leukemia sub-types or cancer as
Irf4 (an oncogene locus which is frequently translocated in
peripheral T-cell lymphomas) [7], Depdc6 (when over-
expressed, it increases survival of hepatocellular carcinoma
cells) [9] and Als2cl (a tumor-suppressor gene that contri-
butes to the tumorigenesis of head and neck squamous cell
carcinoma) [10]. These results validate our new microarray
analysis. More interestingly, we also found other genes that
had never been associated with leukemias nor with other
types of cancer, or had no assigned function such as the
Exoc3l4 [23], Hectd2 [24,25] and AU014947. The complete
a NIH/3T3 pcDNA3.1A
mPARM-1-pcDNA3.1A hPARM-1-pcDNA3.1A
S: 2.6% S: 6.1%
S: 11.9% S: 14.9%
G2/M: 1.9% G2/M: 4.4%
G0/G1: 95.5% G0/G1: 98.3%
G0/G1: 83.0% G0/G1: 80.2%






















Figure 5 Effect of mPARM-1 and hPARM-1 on cell cycle of NIH/3T3 cells. (a) Synchronized NIH/3T3 cells were either untransfected, or
transfected with the empty vector (pcDNA3.1A/Myc-His), murine or human Parm-1 constructs. Cells were fixed at 72h post-transfection, stained
with propidium iodide and analyzed for cell cycle phase distribution. Percentages of cells in different phases of cell cycle were determined with
the ModFit software. (b) Proliferation of control pcDNA3.1A/Myc-His, mParm-1-pcDNA3.1A or hParm-1-pcDNA3.1A transfected NIH/3T3 cells was
analyzed using BrdU, 48h after transfection. DAPI labeled nuclei are in purple and cells that have incorporated BrdU are in green. Representative
fields were photographed. (c) The percentage of proliferating cells was determined using the following formula: % of proliferating cells =
(number of BrdU incorporating cells/total number of DAPI stained cells) * 100. Values were normalized relative to control cells. For a, b and c,
similar results were obtained using either PARM-1 tagged GFP or Myc-His (data not shown). All results represent the average of three
independent experiments. Statistical analysis was performed using one-way analysis of variance (*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001).
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markers, oncogenes or tumour suppressors for T-CD8+
leukemias, is presented in Table 1.From this list, we focused on the 9130213B05Rik that
corresponds to the conserved mParm-1 gene (Additional
















































Figure 6 Effect of mPARM-1 and hPARM-1 on proliferation and on anchorage-independent growth of NIH/3T3 cells. (a) NIH/3T3 cells were
transfected with pEGFP-N1 (GFP), mParm-1-GFP and hParm-1-GFP expression vectors. After 48h post-transfection, 1x104 cells were resuspended in medium
containing 2.5%, 5.0% or 10% of bovine serum. Medium was changed every two days. Cells were fixed and stained after 5 days with 0.2% methylene blue
and 50% methanol and photographed at 40X magnification. (b) NIH/3T3 cells were either untransfected or transfected with pcDNA3.1A/Myc-His empty
vector, mParm-1-pcDNA3.1A or hParm-1-pcDNA3.1A expression vectors. Cells (5.103) were plated in soft agar as described in «Colony formation in soft
agar». After three weeks, cells were observed with an optical microscope (Ernst Leitz, 6MBH Wetzlar) and representative fields were photographed using a
numerical camera (Nikon coolpix 4500; original magnification x40). (c) For each image, the number of colonies formed in soft agar was scored using NIH
ImageJ software Version 1.42l. (d) Cells were untransfected or transiently transfected with pEGFP-N1 empty vector, hParm-1-GFP, ΔCT-GFP and ΔEC-GFP
expression vectors. As a positive control, activated Ras (EJ 6.6) expression vector was used. For b and c, similar results were obtained using either PARM-1
tagged GFP or Myc-His (data not shown). The same experiment was done as for full-length constructs. All results represent the average of three
independent experiments. For panels (c) and (d), the number of colonies in transfected cells was compared to untransfected cells and statistical analysis
was performed using one-way analysis of variance (*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001).















Figure 7 mPARM-1 and hPARM-1 proteins activate ERK1/2, PI3K/AKT, and STAT3 signaling pathways in NIH/3T3 cells. NIH/3T3 cells were
either untransfected or transfected with empty vector, hParm-1-pcDNA3.1A/Myc-His, mParm-1-pcDNA3.1A, respectively. After 48 h, cell lysates
were extracted with specific buffer containing proteinase and phosphatase inhibitors and 30 μg of proteins were resolved by 12% SDS-PAGE.
Following protein transfer, PVDF membranes were probed with (a) anti-phospho-ERK1/2 (Thr202/Tyr204), (b) anti-phospho-AKT or (c) anti-
phospho-STAT3 (All from cell Signaling; 1:1000) antibodies. Loading of equal amount of protein was verified using anti-anti-p44/42 MAPkinase
(ERK), anti-AKT, anti-STAT3 (All from cell Signaling; 1:1000) and anti-β-actin antibodies. Expression of murine and human PARM-1 proteins was
verified using an anti-Myc antibody (exemplified with only one membrane). Experiments were performed in triplicate.
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(Figure 1).
Our interest for this gene was drained by the fact that
Parm-1 was poorly characterized and had never been
clearly associated with cancer. Indeed, the rat Parm-1 is
over-expressed in prostate epithelial cells after androgen
deprivation following castration [26]. However, its
human counterpart expression is increased by androgen
in the LNCaP prostate cancer cell line and decreased in
the CWR22 xenograft upon castration [17]. Moreover,
ectopic expression of hParm-1 in human prostate cancer
cell line enhances their proliferation [17]. However, the
rat Parm-1 had no effect on rat cancer cell line [27]. In
contrast, even if in vivo models demonstrated that over-
expression of Parm-1 is not implicated in apoptosis [26],
in vitro models suggested that Parm-1 is indirectly in-
volved in the survival program [27]. Also, it was demon-
strated that Parm-1 silencing in rat cardiac myocytes
enhanced apoptotic response to endoplasmic reticulum
stress [28]. Due to these conflicting data, we further
characterized the function and determined the onco-
genic potential of PARM-1.
The human mucin family can be sub-classified into
secreted and membrane-associated mucin forms [14,29,30].
The extracellular domain of most transmembrane mucins
is released from the cell surface [14]. Since PARM-1 shares
similar structure with the membrane-associated mucins
(Figure 2a and 2b), we determined whether the EC-domain
of this highly conserved protein is also released. We
showed that hPARM-1 is weakly intact secreted protein
(Figure 3 and Additional file 2: Figure S2). This result,
although unexpected for proteins of the mucin family, cor-
relates with data reported for many other type I transmem-
brane proteins such as APP [31], N-CAM [32], insulin
receptor [33], recombinant EGF precursor [34], and c-Kit
receptor proto-oncogene [35].
Our results for PARM-1 subcellular localization agree
with previous report [17], for hPARM-1 and extend our
observations to the mPARM-1. Indeed, we show that
both proteins co-localized within the Golgi and at early
and late endosomes but weakly localized at the plasma
membrane (Figure 4). The same localization was ob-
served in NIH/3T3 cells transfected with ΔEC-GFP and
ΔSP-GFP mutants (Figure 4g and 4h). However, EC-GFP
and ΔTM-GFP mutants showed a GFP-like localization
(Figure 4i and 4j) and ΔCT-GFP mutant predominantly
showed plasma membrane localization (Figure 4k).
These results suggest that TM probably determines the
Golgi-endocytic pathway localization. Such observation
had already been reported for other proteins as the type
I transmembrane BACE1 protein. BACE1 is mainly lo-
cated in the distal Golgi membrane but not considerably
present at the plasma membrane of neuroblastoma cells.
It was demonstrated that the TM-domain determines itsTrans-Golgi Network (TGN) localization [36]. Our results
also suggest that CT-domain inhibited plasma membrane
localization (Figure 4k). This is reinforced by the fact that
mutations in the CT (287YGRL290 to 287AGRA290) induced
PARM-1 plasma membrane localization [17]. This YGRL
motif acts as a tyrosine-based plasma membrane internal-
ization signal [37] also present in Syntaxin-6 (STX6) pro-
tein which is localized to the TGN. Importantly, it was
demonstrated that deletion of this motif prevents STX6 in-
ternalization and induces its plasma membrane accumula-
tion [38]. Our data suggest that YGRL motif induces
hPARM-1 internalization. Indeed, we showed that the
internalization process of hPARM-1 was temperature-
dependent, very dynamic at 37°C and dramatically inhibited
at 4°C (Additional file 3: Movie S1). These results suggest a
very quick internalization for hPARM-1 and may explain
that the protein remains barely detectable at the plasma
membrane.
It has been established that endosomes and endocytic
proteins can traffic via microtubules [39,40]. Our data
indicated the important role of microtubules in PARM-1
trafficking. In fact, PARM-1 co-localized with the micro-
tubule cytoskeleton (Figure 4l) and depolymerisation of
its network with nocodazole induced a dramatic inhib-
ition of PARM-1 trafficking accompanied by an accumu-
lation of an important portion of PARM-1 at the cell
periphery (Additional file 4: Movie S2). We also found
that hPARM-1 co-localized with caveolin-1 (Figure 4m).
This preliminary result suggests that PARM-1 internal-
ization may be mediated via the caveolae. Further inves-
tigations will be needed to confirm the involvement of
caveolin-1 in this process.
It is known that mucins are implicated in cancer deve-
lopment [29] but there were no convincing data yet on the
role of Parm-1 in cellular transformation. We showed that
PARM-1 enhanced the proliferative capacities (Figure 5)
and confer the serum-independent growth to NIH/3T3
cells (Figure 6a) suggesting that it could induce an auto-
crine loop in cells thus stimulating their proliferation in
absence of growth factors. Using the classical NIH/3T3
colony formation in soft agar test, we demonstrated that
ectopic expression of PARM-1 conferred anchorage-
independent growth to the cells and we found that both
deletion mutants (ΔCT-GFP and ΔEC-GFP) seem to retain
part of their ability to confer this capacity to the cells
(Figure 6b-d). These results let us speculate that the TM-
domain should play an important role in the protein func-
tion especially in its targeting toward the appropriate cell
compartment. It also suggests a complementary or collab-
orative role for EC- and CT-domains, respectively, with
TM to induce anchorage independence. Similar results
were reported for the MUC1 protein where EC- and
CT-domains contribute separately to the cancer cell line
invasiveness and metastasis [41].
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leading to proliferation and provided first evidence on
the role of PARM-1 in ERK1/2 and especially in AKT
and STAT3 dependent signaling pathways (Figure 7).
These pathways are a part of a more complex process
leading to cell proliferation enhancement. In fact, the
AKT is implicated in cell survival, growth and prolifera-
tion [21]. ERK1/2 is also implicated in the cell prolifera-
tion. Interestingly, these two pathways are constitutively
activated in several human cancers [20]. Moreover, it is
known that the STAT3 Ser-727 is phosphorylated by
ERK1/2 [42,43] and that STAT3 is also implicated in the
proliferation tumor-derived cell lines [44]. In summary,
activation of ERK1/2, AKT, and STAT3 shed further
light on the mechanism by which PARM-1 may contrib-
ute to transformation.Conclusions
Overall, our results strongly support an oncogenic role
for Parm-1, member of the mucin family, especially in
T-CD8+ leukemia and enable us to propose the follow-
ing model: newly synthesized protein accumulates to the
Golgi where post-transcriptional modifications occur
(glycosylation and probably dimerization). A major
fraction of PARM-1 protein will be retained in this com-
partment via its TM-domain, which seems to play a de-
terminant role in the oncogenic potentiality of the
protein. Certain amount of the protein will be packaged
in vesicles for transport to the plasma membrane where
a minor fraction of the entire PARM-1 will be secreted
and could serve as a ligand (unknown receptor), which
in turn leads to the activation of the downstream signal-
ing pathway. In parallel, the YGRL motif will induce the
rapid internalization and recycling of the intracellular
protein, a prerequisite for its activity indicating that
non-secreted PARM-1 could act as a new receptor or
transporter. These data suggest a complex role for
PARM-1. Further studies are required to better under-
stand PARM-1 functions and could provide new tools to
develop new therapeutic approaches in the treatment of
human cancer.Methods
Mice sample collection and flow cytometry
To generate leukemias, newborn NFS, FVB/n or Balb/c
mice were injected intraperitoneally with GV-1.4 (1. 106
PFU) or GV-1.2 (3. 106 PFU) viral particles [1].
Moribund mice were sacrificed. Lymph nodes, thymus,
bone marrows and spleens were harvested for flow cy-
tometry analysis [1,3] and RNA extraction [3]. All the
experimental procedures were approved by the Animal
Care Committee of Université du Québec à Montréal.Microarrays and gene expression analysis
Using the microarrays data set normalized from our an-
terior study [3], the RMA values of the 45000 probsets
were used to identify differentially expressed genes in T-
CD8+ leukemias. Genes were selected according the fol-
lowing criteria : the expression signal intensity did not
vary in B leukemias versus control B-cells and the ex-
pression signal intensity was either significantly higher
(up-regulated), or lower (down-regulated) in T-CD8+
leukemias versus control cells (fold-change of 4). The
microarray dataset was deposited at Gene Expression
Omnibus under the accession number GSE12581 [3].
Semi-quantitative RT-PCR
Total RNA (100 ng) was reverse transcribed using the
Omniscript enzyme (QIAGEN) and the oligo(dT) pri-
mer. The semi-quantitative PCR reactions were
performed with the Taq polymerase kit (Feldan) using an
RT reaction corresponding to 10 ng of RNA samples
and to 2 ng for actin, (94°C for 3 min, 94°C for 45 s,
56°C for 45 s, 72°C for 30 s with a final extension at
72°C for 10 min). Annealing temperature and number of
cycles were optimized for each gene.
Plasmid constructions
The cDNA of the complete coding region of mParm-1
and hParm-1 were generated by standard PCR amp-
lification method using primers containing specific
restriction sites. The PCR products were then inserted
in-frame within the pEGFP-N1 (Clontech Laboratories) or
pcDNA3.1/Myc-His(+)A (Invitrogen) vectors. Deletions
were generated using specific primers that amplify the
specific region of interest and the PCR products inserted
in-frame in pEGFP-N1.
Cell culture
NIH/3T3 and Jurkat T-cells were obtained from ATCC
(Rockville). NIH/3T3 cells were grown in DMEM
medium supplemented with 10% CS and Jurkat cells
were cultured in RPMI supplemented with 10% FCS
(Invitrogen). 50 U penicillin and of streptomycin (Gibco,
Invitrogen) were added.
Confocal microscopy
For transient transfection, Jurkat cells (107) were
transfected with 15 μg plasmids by electroporation
with the Gene Pulser System (Bio-Rad). NIH/3T3 cells
were transfected using the polyfect reagent (Qiagen).
Both pEGFP-N1 (control) and GFP-tagged mParm-1 or
hParm-1 genes were used.
Localization of mPARM-1 and hPARM-1 was performed
by confocal microscopy 48 h after transfection. For cell sur-
face membrane co-localization (CellMask™ Plasma Mem-
brane Stains (Invitrogen)), Jurkat cells were pelleted 48 h
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at 37°C on polylysine coated glass slides [3]. For co-
localization experiments, NIH/3T3 cells were plated on
glass coverslips, grown at 50% confluency, and transfected
as described above. After 48 h of transfection, cells were
fixed with 4% paraformaldehyde, followed by PBS washes
and permeabilization with 0.1% Triton X-100 in PBS. Cells
were blocked in PBS with 10% goat serum, 10% BSA and
0.1% triton, and incubated with primary antibodies. Cover-
slips were incubated with Alexa-Fluor-568-conjugated sec-
ondary antibody (1/1000, Invitrogen), washed with PBS,
mounted onto slides using Prolong Gold antifade reagent
(Invitrogen) and observed by confocal microscopy.
For live cell imaging, cells were transfected and sub-
cultured into dishes containing glass coverslip. After 48 h,
glass coverslips were transferred to coverslip-cell chamber
and maintained at 37°C or at room temperature if cells
were previously incubated at 4°C before imaging.
Western blot analysis
NIH/3T3 cells were homogenized in lysis buffer (50 mM
Hepes, pH 7.5, 150 mM NaCl, 10 mM sodium pyro-
phosphate, 100 mM sodium fluoride, 1.5 mM MgCl2, 1
mM EGTA, 200 μM sodium orthovanadate, 1 mM
phenylmethylsulfonyl fluoride, 10% glycerol, and 1%
Triton X-100) supplemented with a complete protease
inhibitor cocktail (Roche) and phosphatase inhibitors
(Sigma). Cells were incubated for 30 min at 4°C, and
centrifuged at 15,000 X g for 10 min at 4°C.
For secretion experiment, NIH/3T3 supernatant was
collected, centrifuged at 500 X g for 5 min and concen-
trated twenty times with a 10 kDa cut-off Amicon Ultra
(Millipore). Secreted and cell lysate proteins were
separated on SDS-PAGE and transferred to PVDF mem-
brane. Membranes were blocked in buffer (PBS, 0.1%
Tween 20 [PBS-T] with 5% nonfat dry milk) and incu-
bated overnight at 4°C with primary antibodies.
Membranes were incubated with horseradish peroxid-
ase–conjugated secondary antibodies diluted in blocking
buffer and signal was revealed by Immobilon Western
HRP reagent (Millipore).
Colony formation in soft agar
To determine the anchorage-independent growth, col-
ony formation was tested in soft agar as previously de-
scribed [3,45]. Briefly, NIH/3T3 cells were transiently
transfected with the empty vector (pcDNA3.1A/Myc-His
or pEGFP-N1), Ras EJ 6.6, mParm-1-pcDNA3.1A or
mParm-1-GFP and hParm-1-pcDNA3.1A or hParm-1-
GFP expression vectors. After 48 h, cells were mixed
with melted 0.3% agarose in DMEM medium and seeded
on top of a 0.6% agarose base layer containing the same
medium. Cells were fed twice a week for 4 weeks and
observed with an optical microscope.Cell cycle analysis
Flow cytometry was performed using a FACScan flow
cytometer (Becton Dickinson). Briefly, 1x106 cells
were pelleted, resuspended in 0.2 ml of PBS, added to
ice-cold 70% ethanol and incubated overnight at 4°C.
Cells were pelleted, resuspended in propidium iodide (40
μg/ml)-RNase (100 μg/ml) solution for 30 min at 37°C
and analyzed by flow cytometry for their DNA content.
Bromodeoxyuridine (BrdU) incorporation
BrdU incorporation was monitored using a 5-Bromo-
2’-deoxy-uridine labeling and Detection kit I (Roche).
Briefly, 48h transfected cells were incubated in the
presence of BrdU, fixed with ethanol, washed with PBS
and incubated with mouse monoclonal anti-BrdU
antibody (clone BMC 6H8). Cells were incubated with
an anti-mouse immunoglobulin-fluorescein antibody
solution. Cells were incubated in a solution of DAPI
(15 000), mounted onto slides using Prolong Gold
antifade reagent (Invitrogen) and observed by fluores-
cent microscopy.
Cell growth in low serum conditions
NIH/3T3 cells were transiently transfected as mentioned
above and 48 h later, cells were seeded at a low density
in DMEM containing 2.5%, 5% or 10% CS for 5 days.
Cells were fixed, stained and photographed.Additional files
Additional file 1: Figure S1. Alignment of deduced amino acid
sequences for eight species of PARM-1 protein. Alignment of Homo
sapiens (NP_056208_2), Mus musculus (NP_663537_1), Pan troglodytes
(XP_001155067_1), Pongo abelii (NP_001127394_1), Sus scrofa
(NP_001230645_1), Bos taurus (NP_001069239_1), Rattus norvegicus
(NP_775137_1), and Gallus gallus (XP_429964_2) proteins. The most
conserved amino acids are represented in red and the unconserved one
in blue. A color code is presented in the top of the figure.
Additional file 2: Figure S2. PARM-1 protein profile and secretion by
NIH/3T3 cells. Immunoblotting of lysates (30 μg) from NIH/3T3 cells
transiently transfected with expression vector containing full-length
hParm-1 or mutants using (a) an anti-hPARM-1 antibody (Sigma; 1:1000)
or (b) an anti-GFP antibody (Santa Cruz Biotechnology; 1:1000). Culture
supernatants from these cells were collected, centrifuged, concentrated
and subjected to SDS-PAGE (12%) and hPARM-1 protein was detected by
western blot as above. Two exposures are presented.
Additional file 3: Movie S1. Temperature effect on hPARM-1-GFP
vesicles trafficking. NIH/3T3 cells were transfected with hParm-1-GFP
construct. After 48h, living cells were either maintained at 37°C (left
panel) or incubated for 1h at 4°C (right panel). Cells were then analyzed
by confocal microscopy and images were collected at a rate of 2
seconds over a period of 10 min.
Additional file 4: Movie S2. Effect of microtubule depolymerization on
the trafficking and localization of hPARM-1 protein. NIH/3T3 cells
expressing hPARM-1-GFP protein were incubated for 30 min with 1 μg/ml
nocodazole (an agent interfering with microtubules polymerization) to
disturb the microtubulin cytoskeleton. Cells were then analyzed by
confocal microscopy. Images were taken at a rate of 2 seconds over a
period of 10 min.
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